Amgen, a biopharmaceutical company based in Thousand Oaks, California, has announced a dividend of $2.38 per share for the third quarter of 2025. This decision was made by the company’s Board of Directors and will be paid on September 12, 2025, to all shareholders on record as of the close of business on August 22, 2025.
This dividend underscores Amgen’s commitment to returning value to its shareholders amidst a backdrop of continued innovation in the biotechnology sector. The company has a long-standing reputation for developing cutting-edge therapies, particularly in areas such as cancer, heart disease, and other serious conditions.
Amgen’s Commitment to Innovation and Growth
Founded over 40 years ago, Amgen has played a pivotal role in establishing the biotechnology industry. The company actively engages in discovering, developing, and delivering innovative medicines that have the potential to improve patient outcomes significantly.
In 2024, Amgen received recognition as one of the “World’s Most Innovative Companies” by Fast Company and was listed as one of “America’s Best Large Employers” by Forbes. These accolades reflect the company’s ongoing efforts to leverage technology and human genetic data in its research and development processes.
Amgen’s robust pipeline includes treatments targeting various diseases, including its marketed product Otezla® (apremilast), as well as its recent acquisitions of ChemoCentryx, Inc. and Horizon Therapeutics plc. These strategic moves are expected to enhance Amgen’s capabilities in delivering effective therapies and expanding its market reach.
Financial Outlook and Shareholder Value
The declaration of the dividend aligns with Amgen’s broader financial strategy to provide returns to shareholders while investing in its growth initiatives. It is important to note that fluctuations in business performance can impact the company’s ability to declare future dividends, as highlighted in Amgen’s forward-looking statements.
These statements encompass potential risks and uncertainties related to various factors such as market competition, regulatory developments, and the global economic climate. Amgen remains vigilant in navigating these challenges, ensuring its operations and product pipeline are resilient.
As a member of the Dow Jones Industrial Average and the Nasdaq-100 Index, Amgen continues to be a significant player in the biotechnology sector. The upcoming dividend payment is a testament to its commitment to maintaining a strong financial position while fostering innovation in healthcare.
For further information, visit Amgen’s official website or follow the company on social media platforms.
